Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis.

Carriers of a mutation in the prothrombin (clotting factor II) or factor V gene have a 2- to 4-fold greater risk for venous thromboembolism than subjects without the mutations. Whether both mutations also predispose to recurrent venous thromboembolism is unclear. Outpatients who had a first episode of proven symptomatic deep-vein thrombosis and a long-term follow-up were studied. The outcome measure was the cumulative incidence of confirmed venous thromboembolic complications. Two hundred fifty-one patients were enrolled in the study. Mean duration of follow-up was 8.3 years. The prothrombin gene mutation was demonstrated in 27 patients (prevalence, 10.8%; 95% CI, 6.9 to 14.6), and the factor V gene mutation was demonstrated in 41 patients (prevalence, 16.3%; 95% CI, 11.8 to 20.9). The cumulative incidence of venous thromboembolic complications after 10 years was 61.3% (95% CI, 35.7 to 87.9), and the hazard ratio was 2.4 (95% CI, 1.3 to 4.7; P =.004) in patients with the prothrombin gene mutation); the cumulative incidence of venous thromboembolic complications after 10 years was 55.2% (95% CI, 36.4 to 74.0), and the hazard ratio was 2.4 (95% CI, 1.4 to 4.1; P =.001) in patients with the factor V gene mutation. In comparison, the cumulative incidence of venous thromboembolic complications after 10 years was 23.1% (95% CI, 16.2 to 30.1) in patients without the mutations. Prothrombin and factor V gene mutations occur frequently in patients with venous thrombosis and are associated with an increased risk for recurrent venous thromboembolic complications.

[1]  M. Petri.  Management of thrombosis in antiphospholipid antibody syndrome. , 2001, Rheumatic diseases clinics of North America.

[2]  M. Prins,et al.  Recurrent deep vein thrombosis and two coagulation factor gene mutations: quo vadis? , 1999, Thrombosis and haemostasis.

[3]  M. Margaglione,et al.  Coexistence of Factor V Leiden and Factor II A20210 Mutations and Recurrent Venous Thromboembolism , 1999, Thrombosis and Haemostasis.

[4]  G Leone,et al.  The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. , 1999, The New England journal of medicine.

[5]  B. Wiman,et al.  The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.

[6]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[7]  P. Ridker,et al.  G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. , 1999, Circulation.

[8]  M. Prins,et al.  Is the Prevalence of the Factor V Leiden Mutation in Patients with Pulmonary Embolism and Deep Vein Thrombosis Really Different? , 1999, Thrombosis and Haemostasis.

[9]  E. Minar,et al.  The Risk of Early Recurrent Venous Thromboembolism after Oral Anticoagulant Therapy in Patients with the G20210A Transition in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.

[10]  S. Eichinger,et al.  Hyperhomocysteinemia Is a Risk Factor of Recurrent Venous Thromboembolism , 1998, Thrombosis and Haemostasis.

[11]  M. Margaglione,et al.  Increased Risk for Venous Thrombosis in Carriers of the Prothrombin GA20210 Gene Variant , 1998, Annals of Internal Medicine.

[12]  E. Oger,et al.  Prevalence of 20210 A Allele of the Prothrombin Gene in Venous Thromboembolism Patients , 1998, Thrombosis and Haemostasis.

[13]  E. Svenungsson,et al.  Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. , 1998, The American journal of medicine.

[14]  F F Costa,et al.  Prevalence of the Prothrombin Gene Variant (nt20210A) in Venous Thrombosis and Arterial Disease , 1997, Thrombosis and Haemostasis.

[15]  M. Makris,et al.  Co-inheritance of the 20210A Allele of the Prothrombin Gene Increases the Risk of Thrombosis in Subjects with Familial Thrombophilia , 1997, Thrombosis and Haemostasis.

[16]  B. Dahlbäck,et al.  The 20210 A Allele of the Prothrombin Gene Is a Common Risk Factor among Swedish Outpatients with Verified Deep Venous Thrombosis , 1997, Thrombosis and Haemostasis.

[17]  T. Baglin,et al.  Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′‐untranslated region of the prothrombin gene , 1997, British journal of haematology.

[18]  E. Minar,et al.  The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden , 1997, Thrombosis and Haemostasis.

[19]  M. Prins,et al.  The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). , 1997, The New England journal of medicine.

[20]  O. Linder,et al.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. , 1997, The New England journal of medicine.

[21]  M. Prins,et al.  Recurrence of venous thromboembolism in patients with familial thrombophilia. , 1997, Archives of internal medicine.

[22]  P. Mannucci,et al.  Inherited Thrombophilia*: Part 2 , 1996, Thrombosis and Haemostasis.

[23]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[24]  P. Mannucci,et al.  Inherited Thrombophilia: Part 1 , 1996, Thrombosis and Haemostasis.

[25]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[26]  P. Mannucci,et al.  Inherited thrombophilia: pathogenesis, clinical syndromes, and management. , 1996, Blood.

[27]  C. Mannhalter,et al.  Probability of Recurrence of Thrombosis in Patients with and without Factor V Leiden , 1996, Thrombosis and Haemostasis.

[28]  P. Ridker,et al.  Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. , 1995, Circulation.

[29]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[30]  Paolo Prandoni,et al.  Accuracy of clinical assessment of deep-vein thrombosis , 1995, The Lancet.

[31]  H. Blom,et al.  Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? , 1995, The Lancet.

[32]  K. Schulman,et al.  Cost-effectiveness analyses. , 1995, The New England journal of medicine.

[33]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[34]  B. Dahlbäck,et al.  Resistance to activated protein C as a basis for venous thrombosis. , 1994, The New England journal of medicine.

[35]  J. Hirsh,et al.  Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. , 1993, Archives of internal medicine.

[36]  F. Rosendaal,et al.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.

[37]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Griffin,et al.  Anticoagulant protein C pathway defective in majority of thrombophilic patients. , 1993, Blood.

[39]  H. Büller,et al.  Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis , 1992, The Lancet.

[40]  A A Connolly,et al.  Deep vein thrombosis. , 1988, BMJ.